How to buy Inhibikase Therapeutics shares | $5.55

Own Inhibikase Therapeutics shares in just a few minutes. Share price changes are updated daily.

Inhibikase Therapeutics, Inc (IKT) is a leading biotechnology business based in the US. It opened the day at $5.74 after a previous close of $5.66. During the day the price has varied from a low of $5.53 to a high of $5.74. The latest price was $5.55 (25 minute delay). Inhibikase Therapeutics is listed on the NASDAQ and employs 3 staff. All prices are listed in US Dollars.

How to buy shares in Inhibikase Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: IKT in this case.
  5. Research Inhibikase Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Inhibikase Therapeutics shares. It's that simple.
The whole process can take as little as 15 minutes.

Inhibikase Therapeutics share price

Use our graph to track the performance of IKT stocks over time.

Inhibikase Therapeutics shares at a glance

Information last updated 2021-03-24.
Previous close$5.66
Change $-0.11
Change % -1.9435%
Volume 14,933
Information last updated 2021-04-29.
52-week range$5 - $11.8
50-day moving average $5.7474
200-day moving average $6.6069
Dividend yield N/A (0%)
Earnings per share (TTM) N/A
eToro Free Stocks

Invest in Inhibikase Therapeutics shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes

Fees for buying 100x Inhibikase Therapeutics shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $200 £1.97
£395.52 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.11
£394.66 total
Capital at risk
Stake logo £0 £50 £2.25
£395.80 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £16.17
£409.72 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £14.18
£407.73 total
Capital at risk
Fineco logo £0 No minimum £3.94
£397.49 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £14.70
£408.25 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Inhibikase Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Inhibikase Therapeutics price performance over time

Historical closes compared with the last close of $5.55

1 week (2021-05-05) 5.31%
1 month (2021-04-16) 5.92%
3 months (2021-02-16) -21.28%


Revenue TTM $698,468
Gross profit TTM $-195,334
Return on assets TTM -23.77%
Return on equity TTM -107.58%
Profit margin 0%
Market capitalisation $52.8 million

TTM: trailing 12 months

How to short and sell Inhibikase Therapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "IKT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 72,193 Inhibikase Therapeutics shares held short by investors – that's known as the "short interest". This figure is 14.1% down from 84,031 last month.

There are a few different ways that this level of interest in shorting Inhibikase Therapeutics shares can be evaluated.

Short interest ratio (SIR)

Inhibikase Therapeutics's "short interest ratio" (SIR) is the quantity of Inhibikase Therapeutics shares currently shorted divided by the average quantity of Inhibikase Therapeutics shares traded daily (recently around 34542.105263158). Inhibikase Therapeutics's SIR currently stands at 2.09. In other words for every 100,000 Inhibikase Therapeutics shares traded daily on the market, roughly 2090 shares are currently held short.

However Inhibikase Therapeutics's short interest can also be evaluated against the total number of Inhibikase Therapeutics shares, or, against the total number of tradable Inhibikase Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibikase Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inhibikase Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0152% of the tradable shares (for every 100,000 tradable Inhibikase Therapeutics shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inhibikase Therapeutics.

Find out more about how you can short Inhibikase Therapeutics stock.

Inhibikase Therapeutics share dividends

We're not expecting Inhibikase Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site